Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SY 5609 (Primary) ; Fulvestrant; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Fallopian tube cancer; HER2 negative breast cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Syros Pharmaceuticals

Most Recent Events

  • 26 Oct 2023 Status changed from active, no longer recruiting to completed.
  • 06 Jun 2023 Results of single agent dose escalation and SY-5609 plus gemcitabine with or without nab-paclitaxel (n=87; As of 13 Jan 2023) assessing the safety lead-ins (SLIs) in patients with advanced solid tumors, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 06 Jun 2023 Results (n=14) presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top